Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;23(10):1718-1721.
doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Andrey Maryandyshev, Emanuele Pontali, Simon Tiberi, Onno Akkerman, Shashank Ganatra, Tsetan Dorji Sadutshang, Jan-Willem Alffenaar, Rohit Amale, Jai Mullerpattan, Sonam Topgyal, Zarir Farokh Udwadia, Rosella Centis, Lia D'Ambrosio, Giovanni Sotgiu, Giovanni Battista Migliori

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Andrey Maryandyshev et al. Emerg Infect Dis. 2017 Oct.

Abstract

We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this therapy is justified for patients with limited options.

Keywords: Europe; India; Italy; MDR TB; Mycobacterium tuberculosis; Russia; Switzerland; TB; United Kingdom; XDR TB; antimicrobial resistance; bacteria; bedaquiline; combination treatment; delamanid; effectiveness; multidrug resistance; multidrug-resistant tuberculosis; mycobacteria; pulmonary; respiratory infections; safety; the Netherlands; tolerability; tuberculosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Global tuberculosis report 2016. Geneva: The Organization; 2016.
    1. Falzon D, Nhat NL, Ernesto J, Karin W. The global response to rifampicin-resistant tuberculosis: current situation and recent trends. Eur Respir J. 2016;48:(suppl 60):PA1903.10.1183/13993003.00424-2016 - DOI
    1. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43:554–65. 10.1183/09031936.00079413 - DOI - PubMed
    1. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49:1602308. 10.1183/13993003.02308-2016 - DOI - PMC - PubMed
    1. Pontali E, Sotgiu G, D’Ambrosio L, Centis R, Migliori GB. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47:394–402. 10.1183/13993003.01891-2015 - DOI - PubMed

MeSH terms

LinkOut - more resources